Impact Factor
3.30
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.48
688 total citations
h5-index
26
h5 depth signal
Cited share
68.4%
203 of 297
Total citations
688
Citation footprint
Metric signal
2.31
External metric anchor
Self-citation
0.9%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
613
Turkey
158
United States
118
United Kingdom
65
Japan
61
Citing Fields of Research
Lung Cancer
400
Respiratory Support
351
Allergies
312
Auto-Inflammatory Disorders
111
Cardiology
99
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,261
Articles tracked across the journal lifetime
Indexed publication set
297
203 cited publications
Last 12 months
94
7.8 publications/month
Open access share
87.2%
82 OA publications in the last year
Leading citing country
China
613 citing publications
Leading citing field
Lung Cancer
400 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v1n1, July 2007-
v1n1, July 2007-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lung Cancer
Respiratory Support
Allergies
Auto-Inflammatory Disorders
Mycobacterial Diseases
Issuing & Sponsoring Bodies
Contributor
Nordic Respiratory Academy
Broad Categories
Pulmonary Medicine
Lung Cancer
Allergies
Respiratory Support
Virology
Noncoding RNA
Cardiology
MeSH Descriptors
Respiratory Tract Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/crj.70234
Open DOI
Development and Internal Validation of a Prediction Model Incorporating Respiratory Muscle Function for CAT Score Deterioration in Stable COPD
Objective: The objectives are to investigate the association between respiratory muscle function and CAT score deterioration in stable chronic obstructive pulmonary disease (COPD) and to develop an internally validated prediction model. ...
02
DOI 10.1111/crj.70233
Open DOI
Epidemiological Characteristics and Clinical Impact of Macrolide‐Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021–2025
Background: Mycoplasma pneumoniae (MP) is a key pathogen causing pediatric community‐acquired pneumonia. Increasing macrolide resistance poses considerable clinical challenges. This study investigated MP epidemiology and macrolide resist...
03
DOI 10.1111/crj.70231
Open DOI
Associations of Serum CIRP and CXCL5 With Prognosis and Neutrophil Extracellular Traps in Pediatric Mycoplasma pneumoniae Pneumonia
Objective: This study aimed to investigate the associations of serum cold‐inducible RNA‐binding protein (CIRP) and C‐X‐C motif chemokine ligand 5 (CXCL5) with prognosis in children with Mycoplasma pneumoniae pneumonia (MPP) and their rel...
04
DOI 10.1111/crj.70162
Open DOI
Issue Information
05
DOI 10.1111/crj.70222
Open DOI
Chinese Expert Consensus on the Testing Process, Quality Control and Clinical Application of Fractional Exhaled Nitric Oxide (2025)
Fractional exhaled nitric oxide (FeNO) is an internationally recognized biomarker for type 2 airway inflammation. With the increasing promotion and widespread use of FeNO testing in China, Chinese experts have previously published consen...
06
DOI 10.1111/crj.70230
Open DOI
Venous Thromboembolism in Severe Community‐Acquired Pneumonia at High‐Altitude Areas: Prevalence, Risk and Outcome
Introduction: High‐altitude exposure and hypoxia may induce a hypercoagulable state, thereby promoting the development of venous thromboembolism (VTE). Few studies have reported the incidence of VTE among patients with severe community‐a...
07
DOI 10.1111/crj.70223
Open DOI
Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes
Immune checkpoint inhibitors (ICIs) have changed therapeutic selections for advanced non–small cell lung cancer (NSCLC). However, comparative evidence versus chemotherapy through ICI monotherapy and chemo‐immunotherapy combination strate...
08
DOI 10.1111/crj.70229
Open DOI
Pulmonary Sarcoidosis in Qatar: Clinical Features, Diagnostic Profile and Treatment Patterns in a Multi‐Ethnic Population
Introduction: Sarcoidosis data from the Middle East are limited, and regional studies have been predominantly single‐ethnicity, leaving phenotyping in the region's diverse expatriate populations unexplored. We characterised pulmonary sar...
09
DOI 10.1111/crj.70228
Open DOI
Pulmonary Surfactant Treatment for Preterm Infants With Respiratory Distress Syndrome: A Nationwide Survey
Background: Pulmonary surfactant is essential for neonatal respiratory distress syndrome (RDS) management, yet national data on how surfactant is used in China are limited. We surveyed current practices and variation in surfactant availa...
10
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Print issues ceased with v. 9, no. 4 (Oct. 2015).
Also issued online.